Cargando…
Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies
Effective antitumor immunity in mice requires activation of the type I interferon (IFN) response pathway. IFNα and IFNβ therapies have proven promising in humans, but suffer from limited efficacy and high toxicity. Intratumoral IFN retention ameliorates systemic toxicity, but given the complexity of...
Autores principales: | Lutz, Emi A., Agarwal, Yash, Momin, Noor, Cowles, Sarah C., Palmeri, Joseph R., Duong, Ellen, Hornet, Vladlena, Sheen, Allison, Lax, Brianna M., Rothschilds, Adrienne M., Irvine, Darrell J., Spranger, Stefani, Wittrup, K. Dane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457244/ https://www.ncbi.nlm.nih.gov/pubmed/36037341 http://dx.doi.org/10.1073/pnas.2205983119 |
Ejemplares similares
-
Co‐Anchoring of Engineered Immunogen and Immunostimulatory Cytokines to Alum Promotes Enhanced‐Humoral Immunity
por: Chang, Jason Y. H., et al.
Publicado: (2022) -
Tregs constrain CD8(+) T cell priming required for curative intratumorally anchored anti-4-1BB immunotherapy
por: Palmeri, Joseph R., et al.
Publicado: (2023) -
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
por: Cowles, Sarah C., et al.
Publicado: (2022) -
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
por: Agarwal, Yash, et al.
Publicado: (2022) -
Optimization of an alum-anchored clinical HIV vaccine candidate
por: Rodrigues, Kristen A., et al.
Publicado: (2023)